Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (clinicaltrials.gov) - Oct 15, 2026 - P2 | N=70 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2026 ➔ Oct 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2028
Trial completion date • Trial primary completion date • B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|